BCAB (BioAtla, Inc. Common Stock) Stock Analysis - Analyst Ratings

BioAtla, Inc. Common Stock (BCAB) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAB trades at $3.62 with a market cap of $6.50M and a P/E ratio of -0.73. BCAB moved -3.36% today. Year to date, BCAB is -82.97%; over the trailing twelve months it is -81.51%. Its 52-week range spans $3.26 to $126.25. Rallies surfaces BCAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate BCAB?

The average price target is $0.00.

BCAB Key Metrics

Key financial metrics for BCAB
MetricValue
Price$3.62
Market Cap$6.50M
P/E Ratio-0.73
EPS$-4.97
Dividend Yield0.00%
52-Week High$126.25
52-Week Low$3.26
Volume0
Avg Volume0
Revenue (TTM)$2.00M
Net Income$-50.62M
Gross Margin0.00%

BCAB Analyst Consensus

BCAB analyst coverage data. Average price target: $0.00.

Latest BCAB News

Common questions about BCAB

What do analysts rate BCAB?
The average price target is $0.00.
Does Rallies show BCAB price targets?
Yes. Rallies tracks BCAB analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is BCAB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCAB. It does not provide personalized investment advice.
BCAB

BCAB